GE HealthCare Technologies (GEHC) said Tuesday the US Food and Drug Administration has approved a pediatric indication for its Optison ultrasound enhancing agent.
The regulatory approval will help improve the clarity and accuracy of echocardiograms in children to allow cardiologists to diagnose heart conditions, the company said.
Optison was approved for adults in 1997 and this latest approval affirms its safety and efficacy in pediatric patients "of all ages," GE HealthCare said.
Price: 73.93, Change: -0.18, Percent Change: -0.24
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.